# Could Ocugen $OCGN be the next Covid-mutation play?

**URL:** <https://tribe.getbaraka.com/t/could-ocugen-ocgn-be-the-next-covid-mutation-play/212>\
**Category:** Investment\
**Tags:** investment\
**Created:** [4 April 2021 08:19 UTC](https://tribe.getbaraka.com/t/could-ocugen-ocgn-be-the-next-covid-mutation-play/212 "2021-04-04T08:19:37Z")\
**Posts on this page:** 1\
**Page:** 1

<div class="post-metadata">

**Author:** ![ayushkbhatia](https://sea1.discourse-cdn.com/flex019/user_avatar/tribe.getbaraka.com/ayushkbhatia/32/69_2.png) [@ayushkbhatia](https://tribe.getbaraka.com/u/ayushkbhatia)\
**Post date:** [4 April 2021 08:19 UTC](https://tribe.getbaraka.com/t/could-ocugen-ocgn-be-the-next-covid-mutation-play/212/1 "2021-04-04T08:19:37Z")

</div>

Ocugen has inked a partnership with India’s vaccine manufacturer Bharat Biotech to distribute its Covaxin vaccinations in the United States, of which revenue, it shall earn a 45% royalty.

### How is Covaxin different from all the other vaccines in the US?

Enter Covid mutations - the theory that covid-mutations may render existing vaccinations obsolete to an enhanced and more effective virus have been gernering a lot of media attention oflate.

Covaxin plays an important role here because it is (through certain clinical trials), assumed to be one of the few vaccines to show a high defence to current and future mutations of the virus.

Here over the next week, possibly Monday. interim Phase 3 II data will potentially be released for Covaxin and an EUA (Emergency Use Authorization) application will shortly follow for the USA from OCGN. ( **Major Catalyst** )

If you take a look at when Phase 3 Interim II results came out for Pfizer’s vaccine they were only about a month apart.

**Pfizer’s Vaccine, Interim Phase 3 I: Nov 9, 2020** [Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study | Pfizer](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against)

**Pfizer’s Vaccine, Interim Phase 3 II: Dec 10, 2020** [Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine | Pfizer](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-publication-results-landmark)

Sources:

**Covid Mutations already:** [Coronavirus Mutations and Variants: What Does It Mean? | Spokane Regional Health District](https://srhd.org/news/2021/coronavirus-mutations-and-variants-what-does-it-mean)

**Covaxin is different:** [How Bharat Biotech’s Covaxin Vaccine Works - The New York Times](https://www.nytimes.com/interactive/2021/health/bharat-biotech-covid-19-vaccine.html)

**Business Journal Article on CEO & EUA, April 1, 2020:** [https://www.bizjournals.com/philadelphia/news/2021/04/01/ocugen-bharat-biotech-covaxin-covid-vaccine-fda.html](https://www.bizjournals.com/philadelphia/news/2021/04/01/ocugen-bharat-biotech-covaxin-covid-vaccine-fda.html)

This investment thesis is for educational purposes only and is not investment advice. I am not an investment advisor. Your capital is at risk when you invest.